| INTERESTING IMAGE |
|
| Year : 2017 | Volume
: 32
| Issue : 1 | Page : 66-67 |
|
|
[18F]Fluorodeoxyglucose positron emission tomography reveals a complete remission of refractory metastatic melanoma after therapy with ipilimumab
Anna Yordanova1, Carl Schlenkhoff1, Holger Palmedo2, Markus Essler1, Hojjat Ahmadzadehfar1
1 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
2 Institute of Radiology and Nuclear Medicine and PET-CT Center, Bonn, Germany
Correspondence Address:
Hojjat Ahmadzadehfar
Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str., 25 Bonn
Germany
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0972-3919.198490
|
|
|
Ipilimumab (YERVOY) is a monoclonal CTLA-4-antibody with anti-tumor-immunogenic effect and is used to treat malignant melanoma. In this case study, we present [18F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) images of a 37-year-old woman with metastatic melanoma, who was previously treated with interferon-alpha therapy and dacarbazine and still progressed. After four cycles of ipilimumab, there was a complete remission of the disease with no evidence of vital, FDG-positive tumor tissue. The follow-up for a total of 1 year confirmed the therapeutic success. This report demonstrates that FDG-PET/CT is a reliable imaging method for response monitoring in metastatic melanoma treated with ipilimumab. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
